Benedikt Schoser et al

What is Pompe disease?

Pompe disease is a rare, inherited disorder caused by the lack of an enzyme called acid **α-glucosidase (GAA)**, which is typically found inside muscle cells.

In healthy muscle cells, the GAA enzyme breaks down the sugar glycogen into glucose.


In **Pompe disease**, the lack of GAA enzyme activity means that **glycogen cannot be** broken down and builds up inside muscle cells. The damage this causes leads to muscle weakness and breathing difficulties over time.

Why did we do this study?


Treatment considerations

Currently, Pompe disease is treated with enzyme replacement therapies (ERTs). These therapies aim to replace the missing GAA enzyme in the muscle cells. However, there are several key challenges to consider when using ERTs in Pompe disease:

ERTs are unstable in the bloodstream



Efficient uptake into muscle and conversion into the most active form of GAA is required





New investigational therapy: cipaglucosidase alfa + miglustat

Cipaglucosidase alfa + miglustat is a new two-component therapy that aims to:

Minimize breakdown of the ERT in the bloodstream before it reaches the target muscle cells

Improve uptake into muscle cells where cipaglucosidase alfa can work like the missing GAA





Safety profile

The **safety** of the

study treatment was

evaluated on an ongoing

basis by

closely monitoring

participants for any

medical issues


An ongoing extension study is investigating whether long-term treatment with cipaglucosidase alfa + miglustat improves the measurements of disease progression in people living with late-onset Pompe disease

-> How did we do this study?

In this extension study, all participants received cipaglucosidase alfa + miglustat every 2 weeks


Cipaglucosidase alfa (20 mg/kg) Infusion into a vein





Miglustat (260 mg) Oral tablets





ERT-naïve group

-> What have we found so far?

Group 1: participants who received cipaglucosidase alfa + miglustat for 104 weeks (in PROPEL and the extension study)



ERT-experienced group

6MWD: a measure of motor function

ERT-experienced participants improved in 6MWD after 52 weeks of treatment with cipaglucosidase alfa + miglustat, and were then stable up to week 104

ERT-naïve participants also improved in 6MWD after 52 weeks of treatment with cipaglucosidase alfa + miglustat, and then improved further up to week 104

Group 2: participants who received alglucosidase alfa + placebo for 52 weeks in PROPEL and then switched to cipaglucosidase alfa + miglustat in the extension study



6MWD: a measure of motor function


ERT-experienced participants were stable in 6MWD after 52 weeks of treatment with alglucosidase alfa + placebo in PROPEL. Stability was maintained after switching treatment to cipaglucosidase alfa + miglustat

ERT-naïve participants showed improvements in 6MWD after 52 weeks of treatment with alglucosidase alfa + placebo. After switching to cipaglucosidase alfa + miglustat, 6MWD improved further to week 104

ERT-experienced group

ERT-naïve group


Week 52



FVC: a measure of lung function

ERT-experienced participants' lung function over 104 weeks, throughout PROPEL and the extension study


ERT-naïve participants showed some decline in lung function worsened over the first 52 weeks of treatment in PROPEL but did not get worse during the extension study




Blood levels of CK: a marker for muscle damage


CK levels improved from baseline in ERT-experienced and ERT-naïve participants treated with cipaglucosidase alfa + miglustat. By week 104, participants who switched treatment from alglucosidase alfa + placebo had similar CK levels to those treated with cipaglucosidase alfa + miglustat from baseline

Lower CK levels may indicate less damage to muscles




Group 1: cipaglucosidase alfa + miglustat in PROPEL and the extension study Group 2: alglucosidase alfa + placebo in PROPEL; cipaglucosidase alfa + miglustat in the extension study





FVC: a measure of lung function


ERT-experienced and ERT-naïve participants had some decline in lung function during the 52 weeks of treatment with alglucosidase alfa + placebo in PROPEL. They then stabilized after switching to cipaglucosidase alfa + miglustat in the extension study up to week 104



Urine levels of Hex4: a marker for glycogen build-up

Hex4 levels in both ERT-experienced and ERT-naïve participants treated with cipaglucosidase alfa + miglustat improved from baseline. By week 104, participants who switched treatment from alglucosidase alfa + placebo had similar Hex4 levels to those treated with cipaglucosidase alfa + miglustat from baseline

Lower Hex4 levels indicate that the treatment may be breaking down glycogen in muscle cells



Group 1: cipaglucosidase alfa + miglustat in PROPEL and the extension study Group 2: alglucosidase alfa + placebo in PROPEL; cipaglucosidase alfa + miglustat in the extension study


^aMeasured in units per liter of blood serum (U/L)

^aMeasured in comparison to the amount of a key protein in urine (mmol/mol creatinine)



-> What do our results mean for people with late-onset Pompe disease?

Participants treated with cipaglucosidase alfa + miglustat had overall improvement or stability in % predicted 6MWD, % predicted FVC and biomarker levels over the course of the extension study



This summary accompanies the manuscript titled '104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)'. ¹Schoser B et al (2021) Lancet Neurol 20:1027–1037; ²Brancaccio P et al (2010) Clin Chem Lab Med 48:757–767; ³An Y et al (2005) Mol Genet Metab 85:247–254. Clinical trial identifier: NCT04138277.

This study was supported by Amicus Therapeutics, Inc., Princeton, NJ, USA.

Medical writing assistance was provided by Kara Filbey, PhD, at Cence (an AMICULUM[®] agency), funded by Amicus Therapeutics, Inc.